What “patent cliff” means for Keytruda in 2025–2026
For Merck’s Keytruda (pembrolizumab), the “patent cliff” refers to the window when patent and related exclusivity protections start expiring or weakening for specific countries and formulations, which can make room for potential competition (for example, biosimilars). The practical impact depends on (1) the exact expiry dates by jurisdiction, (2) whether challengers have litigated to accelerate entry, and (3) how regulators handle biosimilar approvals relative to those expiries.
Because patent-protection timelines vary by country and claim set, coverage is typically tracked at the “patent expiry by jurisdiction” level rather than as a single global date.
When do Keytruda-related patents/exclusivity expire around 2025–2026?
DrugPatentWatch.com tracks Keytruda patent-expiry timelines and is often the fastest way to see which protection layers fall in 2025 and 2026 by country and assignee.
You can check the specific schedule here: DrugPatentWatch.com – Keytruda (pembrolizumab) patent expiry
How big is the commercial hit if biosimilars launch in 2025 or 2026?
The “cliff impact” to Merck depends heavily on whether biosimilars actually launch in those years and how quickly they gain formulary access. In general, when meaningful protection expires and competitors enter, uptake can happen fast—especially in markets where payers push for lower-cost options—leading to a revenue drop from originator pricing.
The magnitude in 2025–2026 is typically driven by:
- Number of countries where exclusivity ends (and when).
- How many competing biosimilars enter early.
- Biosimilar launch timing relative to Merck’s ongoing sales growth in new indications.
- Payer negotiations and tender dynamics (which can intensify after competitors appear).
- Remaining patent coverage beyond the first expiry date (sometimes staggered claim expiries can slow full price erosion).
What’s the litigation risk before a 2025–2026 entry date?
In biologics, companies often litigate around patent scope and “skinny” or other regulatory pathways. That can delay entry even if one protection layer expires, or it can allow entry sooner if courts narrow what remains protected.
For Keytruda specifically, the relevant question for 2025–2026 is whether any late-stage challenges succeed in keeping competitors off the market past the first identified expiry dates.
Does Keytruda still face competition from biosimilars regardless of patent dates?
Even with patent protection, biosimilar developers may be active earlier (for example, through clinical development) so they’re ready to launch as soon as legally allowed. That means the “cliff” is often not a single event; it’s a period where:
- approvals and launch planning happen in parallel,
- early entrants test pricing and payer acceptance,
- and subsequent launches follow based on additional regulatory and litigation outcomes.
What should investors or analysts look for in 2025–2026?
To gauge Merck’s Keytruda patent-cliff risk for 2025 and 2026, look at:
- The country-level expiry schedule (not a single global date).
- Whether the expiries in 2025–2026 are “core” (blocking entry) or narrower (allowing design-around).
- The number of biosimilar products expected in each market.
- Timing of payer coverage changes after launch.
- Any updates to litigation that shift the expected launch window.
DrugPatentWatch’s country-by-country expiry tracking is a good starting point for that timeline: DrugPatentWatch.com – Keytruda patent expiry
Sources
- DrugPatentWatch.com – Keytruda (pembrolizumab) patent expiry